Plus therapeutics advances lead drug rhenium (186re) obisbemeda for patients with leptomeningeal metastases

Austin, texas, feb. 26, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company” or “plus therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced the completion of the respect-lm phase 1 single-dose escalation trial, having determined an rp2d. the respect-lm single-dose escalation trial assessed the safety, tolerability, and potential efficacy of intrathecally administered rhenium (186re) obisbemeda in patients with leptomeningeal metastases (lm).
pstv Ratings Summary
pstv Quant Ranking